EFFICACY
82% reduction in the risk for a patient to progress or die under LUTATHERA® (Lutetium (177Lu) oxodotreotide) compared to high-dose (60mg) octreotide long-acting release (LAR).1*
SAFETY
The overall safety profile of LUTATHERA® is based on pooled data from patients from clinical trials (NETTER-1 phase III and Erasmus phase I/II Dutch patients) and from compassionate use programs.1
QUALITY OF LIFE
Improvement in overall global health-related quality of life (HRQoL) up to week 84 for patients on LUTATHERA® as compared to patients on high-dose (60mg) octreotide LAR.1*